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1. Introduction
More than 10 years after the first sequencing of the human genome and despite major advan‐
ces in scientific and technological expertise into drug research and development processes
(R&D), the fact remains that we are facing a dearth of new drugs. Indeed, the number of drugs
approved by the US Food and Drug Administration (FDA) has roughly fallen to 50% over the
last ten years [1]. Unfortunately for pharmaceutical companies, at present this attrition in drug
discovery combined with the expiration of major product patents logically lead to the devel‐
opment of generics.  Facing both a major medical need and an obvious economical chal‐
lenge, there is an urgent need to make significant improvements in the research output.
Analyses of the clinical trials landscape reveal that a large number of promising drug leads
fail in late stages, mainly in phase II, with an overall failure rate of 67% (Fig. 1a). All studies
agree on the reasons by pinpointing either insufficient efficacy (~55%) or safety issues
(~20%) as major causes of human trials failure [2, 3]. Remarkably, the therapeutic area show‐
ing the largest number of failures is oncology, with only 29% of success rate in Phase II and
34% in Phase III (Fig.1b). Within oncology indications, the status of colorectal cancer (CRC)
is the most dramatic with an overall drug approval of only 3% (Fig.1c) over the last 10 years!
More surprisingly, more than half of the drugs currently approved to treat CRC work
through the general inhibition of DNA synthesis and cellular division, instead of targeting
molecular processes specifically involved in CRC progression (Table 1). These observations
highlight the necessity to both reduce failure rates in the clinic and shorten the time required
for developing innovative therapies.
© 2013 Constant et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
From this perspective, one of the obvious strategies would be:
1. to directly target the key regulators of CRC cancers
2. to streamline the critical Phase II and Phase III to obtain faster and more reliable re‐
sponses regarding the drug’s efficacy.
This strategy may save years of efforts and millions of dollars, giving that the average usual
time for developing a new drug is ten years and with a total cost amount to billions of dollars.
But in contrast, because a new drug has to show a benefit compared to an already approved
treatment, the number of patients involved in a pivotal trials is increasing more and more in
order to reach significance, and a similar trend is noted for the duration of the trial, that is
directly linked to safety. Therefore, regarding the constraints imposed by regulatory author‐
ities nowadays, it seems difficult to save on size and length of clinical trials.
In the mid-1990s, the pharmaceutical community has already attempted to increase R&D
productivity by embarking in a technological shift. That was the time of the inevitable high-
throughput screening, which combined with the “all-Omics” supposed to reduce costs and
blew up success rates [4]. As we have seen, this approach, maybe too reductionist in the
sense that it does not allow getting an idea of the full biological properties (ADME, toxici‐
ty,etc…) of a compound at an early stage, has favored the quantity instead of quality and
has not kept its promises [1].
Today, efforts have to be made to clearly address the early clinical discovery steps, with the
goal to better qualify “leads” to increase the signal-to-noise ratio of drugs entering into clini‐
cal trials. This point of view is supported by the important failure rate subsisting in Phases
III (Fig1b), suggesting an overestimation of the efficacy of candidate molecules during pre‐
clinical tests. One of the important reasons may be the use of irrelevant models or models
not predictive enough. Therefore, the development of relevant and predictive models is key
to increase the quality of preclinical researches and to increase the success rate of new drugs.
Consequently, the foundations of the drug discovery process have to be reconsidered by
giving definitively more emphasis to the quality of preclinical validations and by encourag‐
ing the design of new pertinent models, including human 3D (three dimensional) in vitro cell
models and tissue explants.
This article is intended to give an overview of the current knowledge about CRC and the
different models commonly used to study CRC, in order to identify the most suitable bio-
systems for optimal development of new CRC therapies. The first part will describe the
pathology and its molecular basis, and the various drugs that are currently in clinical use or
under development. Then, in the second part we will review and discuss the use of cancer
cell line collections, genetically engineered mouse models (GEM), primary human tumors
xenografts (PDX) and ex vivo organotypic cultures (EVOC) to identify and validate anticanc‐
er colon therapeutics.
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Figure 1. Success rate of drug development. Overall success rate of clinical trials for phases I-III from 2003 to 2010
corresponding to 4275 drugs and 7300 indications (a), success rate for phase II and III divided according to therapeu‐




Colorectal cancer is one of the major health concerns in the Western world. CRC is the sec‐
ond most frequently diagnosed cancer in men and women, right after lung cancer. It repre‐
sents the second leading cause of cancer-related deaths, both in the United States and in
Europe, with a significant rate of 9% and 13% of total cancer deaths, respectively (Fig.2). The
vast majority (~75%) of colon cancers are sporadic adenocarcinomas, arising from mutations
in the epithelial cells lining the wall of the intestine that is in continuous renewal. CRC often
begins as an adenomatous polyp, a benign growth on the interior surface of the organ. Most
of polyps remain benign, but over the years some of them become progressively more dys‐
plastic, accumulate mutations and progress to carcinoma and ultimately, to metastasis.
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Figure 2. Cancer deaths anticipated in 2011. Estimated leading cancer sites mortality in US and in European Union
(EU-27) for the year 2011 expressed as percent of total cancer deaths. Column diagrams highlight the mortality rate
within the population specifically affected by colon cancer. Rates are standardized to the World Standard Population.




Loss of APC function is the initial molecular event that leads to adenoma formation. Indeed,
germline mutations in the gene APC have been identified as the cause of familial adenoma‐
tous polyposis (FAP), an inheritable intestinal cancer syndrome [5], and APC is mutated in
more than 80% of all sporadic cancers [6]. APC belongs to the WNT signaling pathway (Fig‐
ure 3) where it interacts with other proteins like AXINS and GSK3β to make a complex that
down-regulates the cellular levels of β-CATENIN (see [7] for review). Activating mutations
in β-CATENIN gene have also been observed in more than 10% of CRC [8]. When activated,
β-CATENIN interacts in the nucleus with the transcriptional complex LEF/TCF to induce
the expression of growth promoting genes, like MYC and CYCLIN D1. Additional waves of
genetic and epigenetic alterations (KRAS, P53, etc…) will follow this early set of molecular






Figure 3. Shematic representation of the WNT signaling pathway. WNT proteins bind to receptors of the Frizzled and
LRP families on the cell surface. Through several cytoplasmic components, the signal is transduced to β-CATENIN,
which enters the nucleus and forms a complex with LEF and TCF4 to activate transcription of WNT target genes. Muta‐
tions in APC, Axin and β-CATENIN genes lead to constitutive activation of WNT signaling and ultimately to cancer de‐
velopment.
2.2. Clinical management
It is commonly accepted that CRC results from complex interactions between inherited and
environmental factors, with a large contribution of dietary and life style factors as suggest‐
ed by wide geographical risk variations. However, the primary risk factor of CRC is age,
as 90% of the cases are diagnosed over the age of 50 years [9]. Surgical removal remains
the most efficient treatment for early stage colorectal cancer, and may be curative for can‐
cers that  have not spread.  Patients whose cancer is  detected at  an early,  localized stage
present a 5-year survival around 90% [9]. For these reasons, US and European Union have
implemented preventive screening programs that have contributed to slightly reduce mor‐
bidity and mortality [10].
Unfortunately, as in many other forms of cancer, colon cancer does not display too many
symptoms, develops slowly over a period of several years, and only manifests itself when
the disease begins to extend. Adjuvant chemotherapy in combination with surgery or radia‐
tion is then the usual treatment. However, 5 of the 9 anti-CRC drugs approved by the FDA
today are basic cytotoxic chemotherapeutics that attack cancer cells at a very fundamental
level (i.e. the cell division machinery) without specific targets, resulting in poor effectiveness
and strong side-effects (e.g., oxaliplatin; Table 1).
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Moreover, in more advanced cases, when CRC has spread to distant organs in the form of
metastasis and escape any surgical therapy, the 5-year survival dramatically drops to 12%
[9]. These figures underline the urgent need to expand the standard therapy options by
turning to more focused therapeutic strategies. In recent years, combination of basic chemo‐
therapies with targeted therapies, in the form of humanized monoclonal antibodies directed
against the vascular endothelial growth factor VEGF (Bevacizumab) to prevent the growth
of blood vessels to the tumor, or directed against the EGF receptor (Cetuximab, Panitumu‐
mab) to block mitogenic factors that promote cancer growth, have been introduced as possi‐
ble therapeutic protocol and used routinely to treat standard CRCs, as well as metastatic
CRCs (Table 1). During the preparation of this manuscript (August 2012), another recombi‐
nant protein active against angiogenesis, Aflibercept, has been approved by the FDA for the
treatment of metastatic CRC in second-line therapy (Table 1). This new VEGF inhibitor has
demonstrated a significant advance over currently available therapy in a Phase III study
(improvement in response rate and in overall survival; [11]).
Nonetheless, CRC remains a devastating disease since nearly 35-40% of all patients diag‐
nosed will die from the disease (Fig.2). Accordingly, the expansion and the development
of new path of therapy, like drugs specifically targeting the self-renewal of intestinal can‐
cer  stem cells  -  a  tumor cell  population from which CRC is  supposed to  relapse [12]  –
remains relevant.
Table 1. Anti-cancer colorectal drugs approved by the Food and Drug Administration. Drugs are presented sorted by
type, i.e. small molecule or biologics (including recombinant protein and monoclonal antibody, noted mAb). Source:
National Cancer Institute database, 2012.
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2.3. Designing new therapies
A classical approach of drug design in oncology is to identify modulators of specific signal
transduction pathways that are important for tumor growth, survival, invasion, and meta‐
stasis. Because aberrant WNT signaling has been shown to drive the earliest step of colorec‐
tal tumorigenesis (see before), the WNT/β-CATENIN pathway appears critical for CRC and
therefore represents a target of choice for the development of CRC therapeutics.
 
2.3.1. Oncogenic WNT/β-CATENIN pathway as a therapeutic target
Many experiments have demonstrated that disruption of the WNT signaling pathway lead
to consistent growth inhibition and apoptosis of CRC cell lines and effective inhibition of tu‐
mor growth in CRC animal models. These results can be achieved by modulating the path‐
way at different levels, from the membrane receptor to the final nuclear transcription factors
(Figure 3). A significant number of proof of principle studies have already been published,
including targeted inhibition of WNT1-2, FZD or LRP5/6 receptors by antibodies or inhibito‐
ry fusion proteins [13-15], inactivation of the pathway by re-expression of WIF1 (WNT-in‐
hibitory factor-1) or through restoration of tumor suppressors APC and Axin expression
[16], expression of a dominant-negative mutant to block the transcription factor TCF4 [17],
and finally direct inhibition of β-CATENIN using RNA interfering technologies in vitro and
in vivo [18, 19]. Taken together, these data provide a strong biological rationale for drugging
the WNT/β-CATENIN signaling pathway.
In addition, recent evidence also points to a role for WNT/β-CATENIN signaling in the
modulation of cancer stem cells. It is now well documented that a number of critical path‐
ways regulating stem cell maintenance and normal developmental processes (e.g. HEDGE‐
HOG-GLI, NOTCH, TGF) are also involved in the self-renewal and differentiation of cancer
stem cells whose tumors are initiated [20]. Consequently, in a way similar to the HEDGE‐
HOG-GLI pathway [21], a large number of high-throughput cell-based screening strategies,
mainly designed to disrupt TCF/β-CATENIN interaction, have led to the identification of
promising molecules as inhibitors of WNT/β-CATENIN pathway (reviewed by [22]).
However, currently few of these compounds have progressed beyond the preclinical stages.
To date, the only compound designed to specifically disrupt β-CATENIN is developed for
the treatment of Familial Adenomatous Polyposis (FAP), an inherited form of colon cancer.
This new RNAi-based therapeutic known as CEQ508 consists of a modified E.coli bacterium
that is able to express and deliver a shRNA to the epithelial cells of the gastrointestinal mu‐
cosa after ingestion by the patient [23]. CEQ508, which has shown efficiency in silencing β-
CATENIN and preventing polyp formation in the APCmin FAP mouse model, is now in a
Phase I clinical trial (Table 2).
Alternatively, a possible way of interfering with the WNT/β-CATENIN cascade, even if not
direct, may reside in the manipulation of KLF4 levels. KLF4 (Kruppel-like factor 4) is a tu‐
mor suppressor factor which is typically deficient in a variety of cancers, including colorec‐
tal cancer. In addition to controlling the cell cycle regulator cyclin D1, KLF4 has also been
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shown to inhibit the expression of β-CATENIN [24]. Therefore, the modulation of KLF4 ex‐
pression may represent a novel therapeutic approach for β-CATENIN-driven malignancies.
LOR-253 [25], a compound that stimulates KLF4 through the inhibition of the human metal-
regulatory transcription 1 (MTF1), is currently in a Phase I clinical study (Table 2).
It is noteworthy that despite the significance of this signaling axis for the treatment of spora‐
dic colorectal cancer, none of the therapies engaged to date in CRC clinical trials are directly
targeting WNT/β-CATENIN pathway members. Nonetheless, considering the huge effort
done at the research level to identify potential antagonists and the few candidate already en‐
gaged into preclinical studies, no doubt that innovative therapies will emerge from this
promising pathway in a near future.
 
2.3.2. Acquired tumor resistance and targeted therapies
In the recent years, a cohort of oncogenes, including BRAF, KRAS, NRAS, PI3K, PTEN and
SMAD4, have been found mutated in CRC with significant frequencies ranging from 6%
(NRAS) to 40% (KRAS) [26]. These observations pinpoint one of the most challenging as‐
pects of anticancer therapy that is intrinsic or acquired drug resistance. Indeed, several stud‐
ies have shown that these mutations are associated with the lack of response to Cetuximab
and Panitumumab (anti-EGFR therapies) observed in a subset of chemorefractory metastatic
CRCs, suggesting that the corresponding deregulated signaling pathways are responsible
for the occurrence of resistance of the tumor to the clinical treatment [27-28]. As a result,
downstream key components (mostly protein kinases) of these constitutively activated
growth-related signaling cascades have become targets for drug development. Small mole‐
cules inhibitors of BRAF (ARQ 736), MEK (Selumetinib, PD-0325901), PI3K (PX-866, BEZ235,
BKM120), and MET (Tivantinib) that were able to reverse resistance to EGFR inhibitor thera‐
py in pre-clinical studies [29-31] are currently in CRC Phase II clinical studies (Table 2). This
new class of drugs appears therefore as a promising third-line therapeutic strategy for colon
cancer patients, especially after recurrence of tumor resistance. However, a recent publica‐
tion reporting the apparition of resistance to PI3K and AKT inhibitors mediated by β-CATE‐
NIN overactivation, may temper this enthusiasm. Depending on the tumor status, from pro-
apoptotic tumor suppressor, PI3K or AKT inhibitors could become metastatic inducers [32].
Similar side effect induction mechanisms have also been reported in CRC for the
BRAF(V600E) inhibitor Vemurafenib that triggers paradoxical EGFR activation [33]. All to‐
gether, the complexity of these results supports the arrival of a personalized medicine,
where a careful profiling of tumors will be useful to stratify patient population in order to




2.3.3. New anti-angiogenesis therapies
As previously mentioned, until recently the humanized monoclonal antibody Bevacizumab
against VEGF was the only anti-angiogenesis agent approved by FDA. It is now completed
by Aflibercept, a recombinant protein consisting of the key domains of VEGF receptors 1
and 2. The compound captures and blocks all isoforms of VEGF-A and VEGF-B growth fac‐
tors, as well as placental growth factors [34]. Due to improvement in the understanding of
the critical role of angiogenesis in the maintenance of CRC tumors and the spread of their
metastasis, anti-angiogenesis has become an area of active investigation [35]. However, the
recent failure in Phase III first-line studies of two promising compounds (Sunitunib in 2009
and Cediranib in 2010) has cast serious doubt on that strategy. Therefore, the approval of
Aflibercept provides timely support to the further development of anti-angiogenics as treat‐
ment for metastatic CRC. Today, 4 additional therapeutic agents that target VEGF, Ramucir‐
umab [36], Icrucumab [37], Regorafenib [38] and Vatalanib [39-40] are under clinical
evaluation (Table 2). This battery of anti-angiogenics is supplemented by AMG386, a re‐
combinant peptide-antibody fusion protein (peptibody) which targets another signaling
pathway involved in tumoral angiogenesis, the angiopoietin axis [41]. AMG386, which in‐
hibits the interaction between the ligands ANGIOPOIETIN-1 and ANGIOPOIETIN-2 with
their TIE2 receptor, is currently in Phase II. Finally, a phase III trial was also recently initiat‐
ed (May 2012) to evaluate TAS-102, a combination agent composed of the cytotoxic pyrimi‐
dine analog TFT and a thymidine phosphorylase inhibitor (TPI) with antineoplastic activity
(Table 2). TAS-102 mechanism of action is based on the inhibition of the thymidine phos‐
phorylase (TYMP) also known as the platelet-derived endothelial cell growth factor, a po‐
tent angiogenic factor [42]. In this context, it is important to point out that differences in the
efficiency to block angiogenesis and tumor progression have been observed between pre‐
clinical models and clinical trials, when comparing antibodies with small molecules [35].
These discrepancies in clinical outcome underline the necessity to validate compounds on
relevant models, preferentially based on human tissues, very early during drug develop‐
ment process.
 
2.3.4. Other cellular mechanisms under target
Modifications in the epigenetic landscape are commonly associated with cancer, but on the
contrary to genetic mutations, these changes are potentially reversible and therefore drugga‐
ble. Most of the epigenetic drugs discovered to date modulate DNA methylation or histone
acetylation. Four epigenetic drugs have already been approved by FDA for use in clinic
against various cancers. An additional one, the histone deacetylase (HDAC) inhibitor Resmi‐
nostat [43] is currently being studied in patients with CRC, in a phase I/II trial (Table 2).
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Table 2. Anti-cancer drugs in colorectal clinical trials. This table gives an overview of the main colorectal cancer thera‐
pies being currently evaluated in clinical trials. Drugs are presented sorted by type, i.e. small molecule or biologics. For
each compound, the pathway target and clinical status is provided. Source: National Cancer Institute database, 2012
and the clinical database of the Journal of Gene Medicine (http://www.wiley.com/legacy/wileychi/genmed/clinical).
2.3.5. Unconventional approaches
Oncolytic viral therapy represents an appealing alternative therapeutic strategy for the treat‐
ment of CRC, both as single agent or in combination with existing clinical regimens. Onco‐
lytic viruses, like the vaccinia virus (a virus previously used for worldwide vaccination
against smallpox), have the property to selectively infect and destroy tumor cells with limit‐
ed or no toxicity to normal tissues. These viruses efficiently replicate in tumor tissue, cause
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tumor lyses and stimulate antitumor immune response. During the last decade, numerous
mutants have been engineered to improve their tumor specificity and antitumor efficacy,
and to allow tracking of viral delivering by non-invasive imaging [44]. No less than five on‐
colytic virotherapies are currently evaluated in clinical trials for metastatic CRC indication,
including ColoAd1, derived from an adenovirus [45], NV1020, derived from an Herpes sim‐
plex virus [46], Reolysin, a reovirus [47], and JX-594 [48] and GL-ONC1 [49] both derived
from vaccinia viruses, reflecting the many hopes carried by this emerging treatment modali‐
ty. However, it is noteworthy to mention that there are still some difficulties to viral infec‐
tion. Solid tumors have a complex microenvironment that includes disorganized
surrounding stroma, poor vascular network as well as high interstitial fluid pressure. All
these parameters will limit viral delivery since viral penetration directly depends on cellular
packing density and adhesion between cancer cells [50]. Moreover, hypoxia reduces viral
replication, and therefore oncolytic efficiency, without affecting tumoral cells viability [51].
These observations highlight how choosing the right experimental validation model, e.g. 3D
cell cultures or spheroids in vitro, or patient primary-derived xenografts that retain tumoral
architecture complexity in vivo, will be critical for future clinical success.
This inventory of new drugs for the treatment of colorectal cancer highlights the diversity of
approaches being considered to combat the disease. Whether based on small molecules,
humanized antibodies or modified viruses, their success in further clinical assessment is
largely related to the quality of their preclinical evaluation. This is why both the choice of
appropriate existing model systems and the development of more clinically relevant and
predictive pre-clinical models appear critical in overcoming the high attrition rates of com‐
pounds entering clinical trials.
Current research is also focusing on the development of biomarkers that will be useful for
the early detection of CRC, as well as for fine-tuning drug regimen and following efficacy
during trials and treatments. To date, only a few markers have been recommended for prac‐
tical use in clinic [52] but large-scale genomics technology combined with advanced statisti‐
cal analyses should generate soon new biomarker panels for CRC diagnosis [53]. Then, it
will be interesting to see how these biomarkers could be implemented in preclinical stages
to improve drug selection.
 
3. Preclinical models
3.1. Colon cancer cell lines
It is worth mentioning that most of our understanding of the molecular mechanisms in‐
volved in CRC come from studies done on mouse or human cell lines that represent only a
highly selected fraction of the original tumor and that may have acquired in vitro additional
genetic abnormalities. Moreover, isolated cells grown on plastic dish flooded with growth
factors appear retrospectively as a very poor model system to elucidate human CRC biolo‐
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gy, especially with regard to the importance of growth signaling pathways (EGF/FGF) and
tumor/stroma interactions in CRC progression. Clearly, the scientific community has taken
into account these limitations, as shown by the growing interest for more complex models
(e.g. 3D spheroids). However, although imperfect, colon cancer cell lines still represent a
unique resource that can be extremely valuable in term of genetic manipulation and high-
throughput screening, with cell viability, cell proliferation or promoter specific reporter ac‐
tivity being the usual endpoints followed. Several initiatives have been launched to
maximize their utility in large scale drug discovery programs.
3.1.1. NCI-60 cancer cell lines collection
The NCI60 is a collection of 59 human cancer cell lines derived from diverse tissues, includ‐
ing colon (HT-29, COLO-205, HCT-15), which was established in the early 1990s by the
Sanger institute (http://www.sanger.ac.uk/genetics/CGP/NCI). In an attempt to identify new
active molecules, over 100,000 chemical compounds were pharmacologically tested in this
cell line set. But disappointingly, most of the selected positive candidates were typical cyto‐
toxics, affecting cancer cells via general fundamental cellular processes, like cell cycle regu‐
lation. These cell lines are under further characterization by sequencing for mutations in
known human oncogenes. Interestingly, this resource can be screened on demand for any
chemical or biological agent. As an example, the NCI60 has been recently used to determine
the permissivity of standard cancer cell lines to VACV infection and replication, with the
aim to better characterize viral oncolytic therapeutic strategies [54].
3.1.2. The Cancer Genome Project
The emergence of tumor acquired resistance to pharmacological inhibitors linked to muta‐
tions in driver oncogenes has recently revived the interest for cancer cell lines. Indeed, an
extensive characterization of cell lines at the genomic and genetic levels will allow determin‐
ing a genetic profile predictive of drug sensitivity. Such a signature will help to stratify pa‐
tient population and identify efficient therapeutics combination, as long as cell lines reflect
real tumor biology. In this perspective, the Sanger Cancer Institute has started the genetic
characterization of a panel of 800 cancer cell lines (The Cancer Genome Project, http://
www.sanger.ac.uk/genetics/CGP). Using current high throughput techniques this program
intends to provide information on mutations, copy number variations, single nucleotide
polymorphisms (SNPs) and microsatellite instability of usual cancer cell lines.
3.1.3. The Cancer Cell Line Encyclopedia
Similarly, the cancer cell line encyclopedia project is a joint initiative between The Novartis
Institutes for Biomedical research and scientists from the Broad Institute (http://www.broad‐
institute.org/ccle/home) to provide a detailed genetic and pharmacologic characterization of
a panel of 1000 human cancer cell lines, including more than 60 CRC cell lines. Again, the
ultimate purpose of this project is to establish genetic maps that would predict anticancer
drug sensitivity [55].
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3.1.4. Biomimetic cell culture models
The derivation of a cancer cell line from the primary tumor is not an obvious process, and
for many cancers, few if any cell line can be obtained. A success rate of less than 10% has
been reported for the establishment of human colon cancer cell lines grew immediately in
vitro from fresh tumors [56]. Elasticity of the surrounding microenvironment has been point‐
ed out as a critical parameter of in vitro cell growth. Indeed, culture plastic dishes are much
more rigid than the epithelial wall of the intestine (10000 kPa vs 40 kPa). More importantly,
depending on the stiffness of the substrate, cells can be differentially sensitive to drugs in
term of spreading and apoptosis-induction, notably because of the expression and presenta‐
tion of surface receptors [57]. Therefore, the choice of an appropriate biomimetic substrate
that will preserve the in vivo phenotype appears decisive not only for cell survival but also
for clinical relevance. Soft polymer surface, with different degrees of stiffness reproducing
the original tumor environment have been engineered (ExCellness Biotech) and are now
available to improve 2D or 3D cultures.
3.1.5. Colon cancer stem cell models
Cancer stem cells (CSCs) are a discrete self-renewing tumor cell subpopulation that can dif‐
ferentiate into multiple lineages, drive tumor growth and metastasis. Moreover, CSCs are
thought to be responsible for tumor recurrence after chemotherapy and radiotherapy. One
of the characteristic of the CSCs is their ability to form spherical cell colonies when they are
cultured in chemically defined serum-free medium at a relative low density [58]. This mod‐
el, also called colonospheres, constitutes a unique in vitro system to elaborate therapeutic
strategies that specifically target colon CSCs, like oncolytic adenoviruses developed to target
specific CSCs antigens (e.g. CD44 or LGR5). In addition, sorting of CSCs based on specific
surface epitopes expression has also been used to enrich culture in tumor initiating cells in
order to increase the success rate of cell line establishment and therefore improve cell line
representation for CRC.
 
3.2. Multicellular Spheroid models
Early stage development of novel anti cancer treatment requires in vitro methods able to de‐
liver fast, reliable and predictive results. To select the most active molecule lead in a library,
pharmaceutical industry has turned its attention to High Throughput Screening (HTS) tests
which mimic human tissues. Furthermore, 3-Dimensional (3D) test system has been widely
accepted as being more informative and relevant than classical 2D cell systems. Combina‐
tion of HTS and 3D models such as the multicellular tumor spheroid model has been point‐
ed out having the potential to increase predictability of clinical efficacy from in vitro
validation therefore contributing savings in both development cost and time [59]. Advantag‐
es of spheroids compared to classical 2D cell line culture have been reported [60]. Indeed,
proteomic analysis of multicellular spheroids versus monolayers cultures identifies differen‐
tial protein expression relevant to tumor cell proliferation, survival, and chemoresistance.
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Consequently, spheroids strategy has been used for the screening of new anticancer agents,
like compounds that modulate apoptosis pathways [61].
Standardized spherical microtissue production in a 96 or 384-well hanging-drop multiwell
plate format on robotic platform has been successfully achieved by 3D Biomatrix and In‐
sphero AG. Formation of standardized spheroids rely on the use of A431.H9, a human epi‐
thelial carcinoma cells, [62] or the colon cancer cell line HCT116 [63]. Interestingly, loss of
cancer drug activity in HCT-116 cells during spheroid formation in a 3D spheroid cell cul‐
ture system has been reported [64]. Spheroid cell models also enable the study of colon can‐
cer chemoresistance and metastasis [65].
 
3.3. Colon cancer animal models
3.3.1. Chemically induced animal models
Colon cancer can be induced in mouse by specific carcinogens like 1,2-dimethylhydrazine
(DMH) and azoxymethane (AOM). Exposure of the mouse intestine to these chemicals trig‐
gers rapid and reproducible tumor induction which recapitulates the adenoma-carcinoma
sequence that occurs in human sporadic CRCs, with the notable exception however of the
invasive and metastatic stage. The application of colon carcinogenesis treatment to CRC
mouse model, like the Apcmin/+ animals, results in an increased tumor incidence by up to 6
fold. Interestingly, differences in genetic mutations that arise in chemically induced colon
tumor models are largely carcinogen specific. K-Ras mutations are predominant in the DMH
model, while AOM treated mice exhibit tumors with activating mutations in the β-catenin
gene [66]. These models could therefore be useful to assess therapies targeting specific CRC
signaling axis.
3.3.2. Apc min/+ mice
The multiple intestinal neoplasia (Min) mouse was identified following random mutagene‐
sis with ethylnitrosourea [67]. A mutation in the Apc gene was identified as the cause of the
disease, like in the human Familial Adenomatous Polyposys (FAP). However, Although
Apcmin/+ mice spontaneously form a large number of benign adenomas in the small intestine,
colon tumors develop in fewer than half of the animals, in contrast to human FAP patients
which routinely develop invasive carcinomas.
3.3.3. Genetically Engineered Mouse models (GEMs)
The main purpose for developing genetically engineered mice is to model the human dis‐
ease in order to first better understand the biological processes underlying normal and ma‐
lignant cell physiology, and second to establish a reliable preclinical model mimicking the
true biology of human cancer and useful for drug discovery. In an attempt to accurately
model the phenotype observed in FAP or sporadic CRC patients, a constellation of Apc ge‐
netically engineered mice, all based on the loss of the wild-type Apc allele, have been creat‐
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ed (see [68] for review). To date, GEMs have been extensively used to demonstrate the
function of candidate genes in CRC tumorigenesis, and the fact that tumors occur and devel‐
op naturally in the host constitutes undeniably an advantage of transgenic models compare
to xenograft models.
The main disadvantage, except the time and the cost required to generate and maintain such
animals, lies in the fact that none of these Apc mouse models consistently display metasta‐
sis, while treating metastasis is the current challenge.
 
3.4. Xenograft Models
The development of cancer xenograft models allows in vivo testing required for the predic‐
tive assessment of the clinical tolerability and efficacy of therapeutic agents. For decades,
xenografts have been generated from human tumor cell lines that have been selected by in
vitro culture.
3.4.1. Subcutaneous xenografts
As standard, tumor cells are implanted subcutaneous in the hindflank region of immunodefi‐
cient mice (e.g. Nude, NSG) to prevent rejection. Tumor growth during the treatment period
is monitored either by measuring the tumor mass on the animals using Vernier calipers or by
recording the activity of specific markers, like luminescent (Luciferase) or fluorescent (GFP)
reporters, using non invasive imaging. At the end of the experiment, animals are euthanized
and tumors are collected for histological or genetic analyses. Many applications are possible:
complex growth competition assays can be performed inside a same tumor by injecting a mix
of  genetically  modified tumor cell  population,  each expressing a  specific  reporter  (Red/
Green assay). These assays allow the identification of new oncogenic targets, revealed by growth
advantage, and therefore critical for tumor development [69]. Subcutaneous xenografts are
useful for the study of tumor / stroma / vascular network interactions, which is not possible in
cell lines. Nonetheless, this heterotypic human/mouse model has its limitations since some
murine ligands are not able to activate human receptors (e.g. HGF/MET, [70]). In addition,
some CRC cell lines, even if implanted subcutaneous, can produce distant metastasis to the
lung or the lymphatic nodes, allowing to study the effect of therapies specifically designed
against metastatic dissemination and growth (C. Mas, pers. comm.).
Here it is interesting to note that at the preclinical level, the in vivo antiangiogenic activity of
Sunitinib (see “New anti-angiogenesis therapies” section before) was evaluated in sub-cuta‐
neous xenograft tumor models derived from HT29 and Colo205 human colon carcinoma cell
lines implanted in athymic mice [71-72]. However, thereafter no advantage in anti-tumor ef‐
ficacy could be shown in Phase III trial. Although the reasons for this failure are not clearly
established, the genetic heterogeneity observed in primary CRC patient tumors could ex‐
plain this lack of efficacy: in vitro selected cell lines are not enough representative of CRC
patient’s tumors. This observation suggests that new models including large tumor panels
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able to recapitulate the biological heterogeneity of patient's populations appear necessary
for an accurate evaluation of molecular targeted agents.
3.4.2. Orthotopic xenografts
A number of observations suggest that the behavior of tumor cells can be significantly dif‐
ferent when implanted as a subcutaneous xenograft, compared to their behavior when
grown into the tissue of origin. For these reasons, orthotopic models are thought to be better
predictors of drug efficacy and are more clinically relevant. To this purpose, intracolonic
xenografts have been developed. Technically, a small incision is made in the abdomen of the
immunodeficient mouse, directly over the colon, and CRC cells are implanted under the se‐
rosa of the colon. Local tumor growth on the colon is then monitored. Although more realis‐
tic, the use of orthotopic xenograft models does not guarantee success. The efficacy of
Semaxanib, an antiangiogenic molecule, has been tested in preclinical stages using an intra‐
colonic Xenograft [73] but compound development was stopped after negative results from
Phase III. Again, representation of patient heterogeneity should be taken into account at the
preclinical level.
Finally, if the use of selected tumor lines and the value of the mouse as a host could be ques‐
tionable in xenograft models, the response end points, survival end points, and tumor cell
killing end points that are usually used during in vivo efficacy studies remain in line with
clinical investigations.
3.4.3. Patient-derived xenograft models (PDXs)
In order to circumvent the difficulties of establishing new cell lines, as well as to establish an
in vivo model preserving the histopathological characteristics of the original tumor, investi‐
gators have developed a new xenograft system based on the direct grafting of human tumor
fragment into immunodeficient mice (Figure 4). Several CRC patient-derived xenograft col‐
lections (PDX) have been reported, with an average tumor take rate of over 60% [56, 74-75].
They can be cryopreserved and re-established in mice as needed, or maintained as xeno‐
grafts from mice to mice. Intensive characterization has demonstrated that the architecture
of PDX tumors, their gene expression profile and their chromosomal instability remains
very similar to the parental tumor, even after successive passages [75-76]. Importantly, high
correlation between drug activity in PDX and clinical outcome has been reported, making
this model a valuable pharmacological tool for drug development [74-75]. Moreover, be‐
cause they are derived from tumor fragment, PDX tumors retains the genetic heterogeneity
existing in the original human tumor and are therefore useful for studies exploring acquired
drug resistance mechanisms [75, 77]. The use of PDX as a model for tumor-stroma interac‐
tion is however less obvious since by the fourth passages human tumor stroma is replaced
by the murine host [75]. All together, the above considerations highlight the potential of the
PDX model to accelerate drug development and predictive biomarker discovery in CRC.
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Figure 4. The PDX model. Sequential steps leading to the establishment of a CRC primary Patient-Derived Tumor Xen‐
ograft collection. Briefly, a CRC tumor fragment coming from surgical waste is directly xenografted in an immunodefi‐
cient mouse (Passage 0). After successful engraftment, new fragments are taken from the mouse hosted human
tumor and xenografted again in multiple immunodeficient mice (Passage 1). A collection of fragments from the re‐
sulting tumors can then be cryopreserved in a tissue bank for subsequent experiments or directly re-engrafted in mice
for expansion (P2, P3, etc…). At any step, tumor fragments can be analyzed and compared to the parental tumor in
terms of gene expression, genetic mutations, genomic stability or histopathological features.
 
3.5. Ex-Vivo Organotypic Culture models (EVOCs)
As previously mentionned, current 2D monolayer culture systems are not enough predictive
of in vivo tumor behavior. Indeed, 3D environement is required to provide essential signal‐
ing necessary for establishing and maintaining tumor specific morphogenic programs. Thus,
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an ex vivo methodology which can recapitulate physiological processes and generate multi‐
ple experimental replicates from a single tumor, saving at the same time animals involved in
in vivo experiments will be of great benefit. Ex vivo organotypic cultures (EVOCs), by pre‐
serving the original cancer microenvironement (e.g. epithelial-stromal interaction) fulfill this
requirement. Recently, a number of culture methods have been perfected leading to the de‐
velopment of breast, lung, liver and colon EVOC tumor models [78-81]. EVOCs allow the
evaluation of tumor morphology, proliferation, viability and resistance to therapy in vitro.
Moreover, differential gene-expression profiling across tumor and stroma compartments
can be performed, without any contamination coming from a murine host as seen in xeno‐
graft models [78]. Recent observations have shown that CRC EVOCs mimic closely the in
vivo situation, at the immunohistochemical level [81], but also in term of oncogenic pathway
fonctionallity and pharmacodynamic properties [78]. Importantly, dose-response experi‐
ments with the PIK3 inhibitor LY294002 demonstrate that CRC EVOCs may be used to pre‐
dit tumor sensitivity to drugs in a patient-specific manner [78]. EVOCs represent therefore a
highly promising in vitro tumor model, when combined with automated medium-through‐
put analyses, has the potential to significantly enhance preclinical drug evaluation studies.
4. Conclusion
The development of relevant and predictive models is key to increase the quality of preclini‐
cal researches and to increase the success rate of new drugs. Many progresses have been
made in this area to get as closer as possible to in vivo situations of human CRC cancers.
Even though cell lines and animal models are still indispensable, the Xenograft Models,
EVOCs as well as the 3D culture of CRC cancer cells hold the promises for the development
of new, more efficient and safer drugs.
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